Doctors Are Drowning in Medication Alerts. Seegnal Thinks It Has a Better Way.
Medication errors cost the world an estimated $42 billion a year. Seegnal is tackling the problem with a smarter, patient-specific alert system already used by roughly 15,000 clinicians—and now the company is testing its approach in the U.S.
Every year, errors involving medicines cost the world roughly $42 billion, according to the World Health Organization, which calls unsafe medication practices a leading cause of avoidable harm in health care. Hospitals have used computerized medication alerts for decades. But when those systems generate too many clinically irrelevant warnings, they can create alert fatigue, increasing the risk that important alerts are overridden or ignored.
Seegnal Inc. (TSXV: SEGN) built its business on that failure. Seegnal reports that its platform is in daily use by approximately 15,000 clinicians across Israeli hospitals and health maintenance organizations. What changed in 2026 is that Seegnal expanded inside its largest accounts, began its first U.S. pilot, and listed on a second stock exchange.
The Warnings Doctors Learned to Ignore
Prescribing software works by flagging risk, and the trouble is how much of it gets flagged. In 2021, researchers at Brigham and Women's Hospital, a Harvard Medical School teaching hospital, published a comparison in the journal Drug Safety. They took de-identified records for 657 inpatients that Epic had already processed in live clinical care, then ran the same records through Seegnal's platform. Epic, as configured at Brigham and Women's Hospital, had generated 27,540 medication alerts across that group, about 42 warnings for every patient. Seegnal's platform produced 1,697. The company-funded study was retrospective, one of its co-authors was a paid consultant to Seegnal US, Inc., and the authors said the platform still required prospective evaluation in live clinical use.
In a blinded review of a random sample of alerts, reviewers found Seegnal's warnings substantially more likely to be clinically appropriate. Its inpatient positive predictive value was 83.8%, compared with 3.6% for Epic, while specificity was 99% compared with 0.3%. In a chart review of selected high-risk patients taking at least ten medications, researchers identified 16 adverse drug events and judged that 11 could potentially have been prevented by Seegnal.
Forty-two warnings per patient is not a safety net. It is noise, and clinicians can learn to click straight through it. The industry calls it alert fatigue, and at that volume, clinically important alerts can become harder to distinguish from low-value warnings.
What Seegnal Does Differently
Seegnal's platform is not another tool that simply checks one drug against another. It reads the patient first: their own laboratory results, kidney function, diagnoses, age, allergies and full medication list. A combination that is dangerous for a 78-year-old with reduced kidney function is often unremarkable in a healthy 40-year-old. Many conventional medication-alert systems do not incorporate enough patient-specific context, which can cause them to warn broadly rather than selectively. Seegnal's platform is designed to weigh those patient-specific parameters before an alert is triggered.
Israel First, Now the United States
In February, Seegnal expanded its deployment at Tel Aviv Sourasky Medical Center, Israel's second-largest public hospital and a global referral center treating more than 1.5 million patients a year. The platform now supports approximately 1,200 clinicians and 2,050 medical team members there, under an engagement running to the end of 2027 with an option to extend to 2031.
April brought the Gold Mark from the Standards Institution of Israel, the country's national standards body. In May, Seegnal signed a letter of intent with a U.S. long-term care provider, its first step into the American market. June was busier still: acceptance into the AgeTech Collaborative from AARP, the start of a pilot in the U.S. analyzing that provider's prescription data for medication risks, and an agreement with Nazareth Hospital EMMS, one of the oldest hospitals in northern Israel, on an initial five-year term with recurring subscription fees covering roughly 424 medical staff. In July the shares began trading on the Frankfurt Stock Exchange under the ticker 2I1 alongside the TSX Venture Exchange, which the company expects to widen its reach among European investors.
The Market It Is Stepping Into
Software that helps doctors decide what to prescribe is its own industry, called clinical decision support. Grand View Research valued it at $6.36 billion in 2025 and projects $15.32 billion by 2033, a compound annual growth rate of 11.8%. North America accounted for roughly 43% of 2025 revenue. The firms Grand View names as leading players are almost all large: McKesson, Oracle, Philips and Epic Systems among them.
Seegnal's way into that market is U.S. long-term care, a setting characterized by advanced age, multiple chronic conditions and high rates of polypharmacy. Roughly 1.2 million Americans live in CMS-certified nursing facilities, a population carrying long medication lists, and a national study published in 2011 estimated that adverse drug events caused approximately 99,628 emergency hospitalizations annually among Americans aged 65 and older during 2007 through 2009. The pilot's initial analysis is expected to run 8 to 12 weeks from receipt of the data. Separately, Seegnal is seeking up to C$1.3 million through a non-brokered private placement of up to 4,642,857 units at C$0.28 per unit, each unit comprising one common share and one 36-month warrant exercisable at C$0.50, for general corporate and working-capital purposes. The offering was extended in July and is expected to close on or before August 31, 2026.
The next markers are concrete: whether the U.S. pilot converts into a paid contract, whether more multi-year agreements follow Sourasky and Nazareth, and how quickly the platform moves beyond Israel. Seegnal has the peer-reviewed retrospective data, roughly 15,000 clinicians using the product every day, and a second listing that the company expects to increase its visibility among European and international investors.
Read this next >> The Pill That Could Retire the Needle: What Lipfendra's Approval Means for Cholesterol Medicine
Recent news highlights from Seegnal
Seegnal Announces Listing on the Frankfurt Stock Exchange
Seegnal Successfully Initiates First U.S. Pilot Program
* IMPORTANT NOTICE AND DISCLAIMER: This article is sponsored content released on behalf of Seegnal Inc. (“Seegnal”) and has been prepared, authored, and disseminated by Wall Street Wire. It is paid promotional content authored by the Wall Street Wire editorial team — not independent research, analysis, or journalism. As sponsored content, it carries inherent bias and potential conflicts of interest. Seegnal's role was limited to review for factual accuracy of statements about the company. This article is not an official communication of Seegnal. The article is for informational purposes only and does not constitute investment advice, an offer to sell, or a solicitation of an offer to buy any securities. Wall Street Wire is compensated for this content on a cash-based subscription arrangement; engagement details are available at https://wallstwire.ai/disclosures. The information in this article is based on publicly available sources, including Seegnal's prior press releases and filings, and has not been independently verified. Statements may constitute forward-looking information within the meaning of applicable securities laws; such statements involve risks and uncertainties, and actual results may differ materially. The clinical comparison referenced in this article was funded by Seegnal and was retrospective in design at a single institution; its results may not be replicated in prospective clinical use, and one of its co-authors is a paid consultant to Seegnal US, Inc. Seegnal's participation in the AgeTech Collaborative from AARP Accelerator Program does not constitute an endorsement, recommendation, or sponsorship by AARP or the AgeTech Collaborative of the Company, its securities, or its products or services. References to private companies, transactions, financial measures, or comparable data are drawn from publicly reported sources cited herein and are provided for thematic context only — they do not imply commercial relationships, endorsements, or comparable financial profiles with respect to Seegnal. Readers are encouraged to review Seegnal's public filings on SEDAR+ (www.sedarplus.ca) for full details, including risk factors and any reconciliations of non-GAAP financial measures referenced. Investing in securities involves risk, particularly in venture-stage and microcap issuers; readers should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. For full disclosure information, please visit https://wallstwire.ai/disclosures.
